Where Are We Now? A Clinicians' Guide to the Use of Follow-On Insulin for Patients with Diabetes

Steven V Edelman; Priscilla A Hollander; Eugene E Wright Jr

doi:10.1016/j.amjmed.2017.03.007

Where Are We Now? A Clinicians' Guide to the Use of Follow-On Insulin for Patients with Diabetes

Am J Med. 2017 May;130(5):614. doi: 10.1016/j.amjmed.2017.03.007.

Authors

Steven V Edelman¹, Priscilla A Hollander², Eugene E Wright Jr³

Affiliations

¹ Professor of Medicine, University of California San Diego, Veterans Affairs Medical Center.
² Baylor University Medical Center, Lead Researcher, Baylor Endocrine Center, Dallas, Texas.
³ Consulting Associate, Department of Medicine and Department of Community and Family Medicine, Duke University School of Medicine, Durham, North Carolina.

PMID: 28431671
DOI: 10.1016/j.amjmed.2017.03.007

Abstract

Insulin has been used as a standard treatment for patients with diabetes for almost 100 years. Over time, advances in insulin development have improved its pharmacologic properties. (Online access: http://courses.elseviercme.com/t2dm/666). Most recently, the US Food and Drug Administration approved a novel, follow-on basal insulin agent, with more expected to be commercially available in the near future. With the imminent availability of follow-on basal insulin agents, clinicians need to be aware of the potential benefits and concerns in order to facilitate informed decision making and to provide the best possible advice and guidance to their patients with diabetes. This program will review how follow-on insulin products are developed, manufactured, and receive regulatory approval; evaluate clinical trial data for new and emerging follow-on basal insulin agents; and provide practical information and guidance on how they may be incorporated into clinical practice. While it is unknown how follow-on basal insulins will affect patient outcomes, they have the potential to increase access to treatment among patients with diabetes and reduce healthcare costs.